TrialThe lancet. HIV2025

Simultaneous initiation of dolutegravir-based antiretroviral therapy and once-weekly rifapentine and isoniazid for tuberculosis prevention in antiretroviral-naive people with HIV: an open-label, non-randomised, phase 1/2 trial.

Ethel D Weld et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.